Drugs /

amg 910

Back to Drugs List

Overview

NCI Definition [1]:
A half-life extended (HLE), bispecific T-cell engager (BiTE) antibody that simultaneously binds to two different and as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, AMG 910 targets and binds to the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response.

Clinical Trials

View Clinical Trials for amg 910

Amg 910 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating amg 910, 1 is phase 1 (1 open).

CLDN18 Expression is the most frequent biomarker inclusion criterion for amg 910 clinical trials.

Adenocarcinoma of the gastroesophageal junction and gastric adenocarcinoma are the most common diseases being investigated in amg 910 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Amg 910
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating amg 910 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bispecific t-cell engager antibody amg 910, amg-910, amg910, bispecific t-cell engager amg 910, bispecific antibody amg 910, bite antibody amg 910
Drug Target(s) [2]:
CD3, CLDN18
NCIT ID [1]:
C170815

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.